Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Evaluation of survival data and two new rank order statistics arising in its consideration.

1966 • 7,595 citations

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene

1985 • 1,804 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

1986 • 1,226 citations

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

1992 • 1,190 citations

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1996 • 1,111 citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 • 1,086 citations

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

1997 • 719 citations

p185^HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

1989 • 672 citations

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1999 • 650 citations

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

1990 • 640 citations

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1993 • 501 citations

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1999 • 445 citations

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

1999 • 339 citations

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.

1986 • 231 citations

Bivalence of EGF-like ligands drives the ErbB signaling network

1997 • 226 citations

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

1991 • 208 citations

The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands

1998 • 196 citations

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy

1999 • 196 citations

Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy

1994 • 193 citations

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1996 • 185 citations

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors

1997 • 178 citations

Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.

1988 • 155 citations

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

1995 • 149 citations

Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors

1997 • 145 citations

Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

1996 • 143 citations

PHASE I CLINICAL TRIAL OF A WORLD HEALTH ORGANISATION BIRTH CONTROL VACCINE

1988 • 129 citations

Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.

1988 • 127 citations

Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

1995 • 114 citations

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1997 • 112 citations

The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.

1990 • 112 citations

A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.

1998 • 110 citations

Selection of monoclonal antibodies which induce internalization and phosphorylation of P185^HER2 and growth inhibition of cells with HER2/neu gene amplification

1991 • 109 citations

Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.

1996 • 104 citations

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

1987 • 98 citations

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.

1997 • 97 citations

Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans

1990 • 95 citations

Glycosylation Affects both the Three-Dimensional Structure and Antibody Binding Properties of the HIV-1_IIIBGP120 Peptide RP135

1997 • 86 citations

Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla

1997 • 84 citations

Vaccination with the extracellular domain of p185 neu prevents mammary tumor development in neu transgenic mice

1999 • 84 citations

The Role of the HER-2/neu Oncogene in Gynecologic Cancers

1996 • 76 citations

Peptide vaccines incorporating a ‘promiscuous’ T‐cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity

1993 • 75 citations

Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.

1991 • 74 citations

Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction

1995 • 70 citations

Synthesis and biophysical characterization of engineered topographic immunogenic determinants with .alpha..alpha. topology

1990 • 69 citations

Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185

1993 • 65 citations

Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2

1999 • 61 citations

Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

1999 • 54 citations

Peptides of 23 residues or greater are required to stimulate a high affinity class II‐restricted T cell response

1993 • 53 citations

ErbB Receptor Activation, Cell Morphology Changes, and Apoptosis Induced by Anti-Her2 Monoclonal Antibodies

1996 • 38 citations

Engineered topographic determinants with alpha beta, beta alpha beta, and beta alpha beta alpha topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4).

1993 • 38 citations

Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals

1993 • 27 citations

Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185

1999 • 26 citations

Immunogenicity and antigenicity of a promiscuous T-cell epitope and a topographic B-cell determinant of the protein antigen LDH-C4

1992 • 15 citations

Recombinant epithelial cell mucin (MUC-1) expressed in baculovirus resembles antigenically tumor associated mucin, target for cancer immunotherapy.

1995 • 12 citations

Promiscuous T-cell epitopes of tetanus toxoid and measles virus enhance immune responses to B-cell epitopes of the protein antigen LDH-C4

1993 • 4 citations